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Aim: To illustrate how limitations in the cannabis literature undermine our ability to 
understand cannabis-related harms and problems experienced by users and identify users 
at increased risk of experiencing adverse outcomes of use. Method & Results: 
Limitations have been organized into three overarching themes. The first relates to the 
classification systems employed by researchers to categorize cannabis users, their 
cannabis use and the assumptions on which these systems are based. The second theme 
encompasses methodological and reporting issues, including differences between studies, 
inadequate statistical control of potential confounders, the under-reporting of effect sizes, 
and the lack of consideration of clinical significance. The final theme covers differing 
approaches to studying cannabis use, including recruitment methods. Limitations related 
to the nature of the data collected by researchers are discussed throughout with a focus on 
how they affect our understanding of cannabis use and users. Conclusions: These 
limitations must be addressed to facilitate the development of effective and appropriately 
targeted evidence-based public health campaigns, treatment programs, and preventative, 
early intervention and harm minimization strategies, and to inform cannabis-related 
policy and legislation. 
 




It is estimated that $7.7 billion is expended annually on the enforcement of cannabis 
prohibition in the United States of America alone [1] with presumably several more 
billions spent across the globe. This spending is ineffectual at best, with an estimated 143-




190 million people using cannabis each year (3.3-4.4% of 15-64 years olds globally) [2]. 
The vast majority of these cannabis users will not experience adverse effects of use [3-5], 
nevertheless, the illegal status of cannabis implies that all use is harmful [6].  This 
divergence between policy and evidence has a long history [5,7] and is unlikely to change 
in the short-term [8].  
 
However, this does not mean that we should not push for evidence-based policies, 
strategies, interventions, and treatments. These elements should be based on the actual 
harms of the substance [9-11] and appropriately targeted to those most at risk of 
experiencing adverse outcomes of cannabis use [6].  
 
Movement toward an evidence-based approach is hampered by limitations in the 
literature. These limitations have been organized into three overarching themes: the 
classification of cannabis use and cannabis users; methodological and reporting issues; 
and, approaches to studying cannabis use. Limitations of the data currently collected by 
researchers are discussed in each section as well as avenues for future research being 
suggested. 
 
LIMITATIONS ASSOCIATED WITH THE CLASSIFICATION OF CANNABIS 
USERS AND CANNABIS USE 
Several limitations in the cannabis use literature relate to cannabis use/user classification 
systems employed by researchers, including the assumptions on which these systems are 
based. For example, studies investigating the effects and outcomes of cannabis use tend to 
categorize participants solely on the basis of dependency status or frequency of use (with 
age of onset employed occasionally). This results in a lack of detailed knowledge about 




overall patterns of use and contributes to a failure to explain the differences between 
cannabis users that are evident in society. This situation is related to the validity of 
dependence criteria and diagnoses, the manner in which frequency of use variables are 
utilized for categorization (including current frequency of use, and past year and lifetime 
usage rates), and the assumption that dependent and/or frequent use equates to 
problematic or harmful use.  
 
A diagnosis of cannabis dependence requires that an individual meet a minimum of only 
three of six of the World Health Organization’s International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) criteria [12] or three of seven of the 
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR) criteria [13]. Although these two diagnostic systems are often 
used interchangeably by researchers, they are not directly equivalent systems, and can 
lead to divergent diagnoses [14]. When either of these diagnostic systems is employed in 
the classification of research participants it is generally based on the assumption that the 
relevant dependence criteria relate to actual harms of use, with dependent users, therefore, 
assumed to encounter more use-related harm than non-dependent users. However, none of 
the ICD-10 and DSM-IV-TR dependence criteria directly assesses harms of use. Rather, 
they focus on physical effects of use (e.g., tolerance, withdrawal) or behaviours 
associated with use (e.g., increased time spent on use-related activities). As such, a 
diagnosis of cannabis dependence does not necessarily equate to harmful or problematic 
use of the substance [15-17].  
 
Further, because the nature of the diagnostic criteria increases the likelihood of some 
cannabis users receiving a diagnosis while others with similar usage patterns do not 




[18,19], there is increasing concern that these diagnostic systems may not be valid [4,18]. 
The lack of assessment of the magnitude of cannabis used by an individual (i.e., quantity 
consumed, frequency of use) and the lack of weighting of dependence criteria also means 
that those diagnosed as dependent may actually experience no symptoms of physiological 
dependence [4]. For example, research participants have been reported as meeting 
dependence criteria when using cannabis less than monthly [20] or only once or twice in 
their lifetime [21].  
   
The classification of cannabis users on the basis of frequency of use also has a number of 
drawbacks, impacting on our understanding of cannabis use. First, the comparability of 
study findings is hampered by researchers employing different frequency of use related 
classification systems. For example, there is no consensus among researchers regarding 
the definition of ‘regular users’, ‘heavy users’ or even ‘non-users’ [e.g., 15 vs.17; 22 vs. 
23]. Consensus is also lacking with regard to how to segment frequency of cannabis use 
into time-related categories. For example, current use may be categorised as: ‘not at all’, 
‘once or twice’ or ‘three or more times’ in the last 30 days [24] or as ‘never used’, ‘less 
than weekly’, ‘at least weekly’, or ‘daily’ [25]. This lack of consensus means that a 
particular individual may be arbitrarily classified as either a high or low level user based 
solely on the classification strategy employed in a given study. This affects the external 
validity of findings and means that readers have to be extremely careful when comparing 
and interpreting findings from different studies.  
 
Second, given the dose-dependent nature of cannabiniods [26], it is concerning that there 
is an implicit assumption that more frequent consumption equates to higher dose, with 
minimal consideration given to the actual quantity or quality (potency) of the cannabis 




consumed [21]. This is particularly worrisome when the classification systems employed 
do not even adequately distinguish between users who consume cannabis once a week, 
once a day, or multiple times a day. Validity is also questionable where researchers are 
not specific in relation to what a ‘use’ of cannabis means (i.e., is it one joint/cone, or one 
session of use in which many joints/cones are consumed? And, is a cone equivalent to a 
joint?). To illustrate, according to current published criteria, someone who is classified as 
a ‘daily user’ may have shared one joint of bush leaf with a number of people on most 
days of the past week (at one extreme), or pulled 20 cones of hydroponic buds each day 
(at the other). 
 
Finally, frequency of use classification systems are based on the assumption that frequent 
use equates to harmful or problematic use. However, it is evident in the literature that 
daily cannabis use does not necessarily equate to dependence on the substance (as the 
usual measure of problematic/harmful use) and, conversely, non-daily use does not 
necessarily equate to a lack of dependency [15,17]. Additionally, there are indications in 
the literature that individuals who use cannabis frequently (i.e., daily or near daily) are not 
an homogenous group, with only some engaging in use that could, plausibly, be defined 
as problematic [27-29]. Thus, it is apparent that factors beyond frequency of use and 
dependence must play a role in problematic or harmful use [30,31]. These factors may 
include the social and physical context of use, methods of administration, motivations for 
using cannabis, and subjective effects of intoxication [26, 29-33].   
 
LIMITATIONS RELATED TO METHODOLOGICAL AND REPORTING 
ISSUES 




Methodological issues are responsible for a number of limitations in the cannabis use 
literature, including a lack of correspondence between studies and potential confounding. 
The manner in which cannabis research is reported has also hampered our understanding 
of cannabis use, with the lack attention paid to effect sizes and clinical significance 
affecting our ability to interpret findings.  
 
Inability to Control for Confounding Factors  
Of particular concern is the finding that it is not possible to complete a meta-analysis 
exploring the relationships between cannabis use and psychological and social issues 
because: “…although some measures were similar across studies, no two studies 
measured either illicit drug exposure or psychosocial outcome in the same way. 
Additionally, potential confounding factors were inconsistently assessed across studies...” 
[9][p. 1582]. Importantly, when studies do statistically control for potentially confounding 
factors, such adjustments have led to the attenuation and sometimes elimination of the 
associations between cannabis use and adverse outcomes, such as affective disorders 
[9,22,34,35]. This is pertinent because substance use and psychopathology both share 
common antecedents, such as childhood adversity. Thus, it is essential that common risk 
factors and concomitant substance use are measured and accounted for appropriately. 
 
Similarly, some inconsistencies evident in the literature investigating the effects of 
cannabis use on cognitive function appear to be due to methodological differences 
between studies [36,37], although confounding may also be an issue. For example, 
impaired cognitive functioning is typically evident in people experiencing psychotic 
symptoms/disorders (e.g., schizotypy, schizophrenia, psychosis) and also in people with 
mood disorders [38,39], who are often over-represented within cannabis using 




populations. Consequently, it is not clear whether the deficits in cognitive functioning 
seen in these individuals are related to their comorbid diagnoses, cannabis use, or both. 
 
Effect Sizes 
Another issue of concern is that most researchers base interpretations of their findings on 
levels of statistical significance, often without reporting effect sizes. This is particularly 
troublesome in relation to large general population-based studies with many thousand 
participants where statistically significant results may be more a reflection of statistical 
power than an indication of the actual strength of the association between variables. For 
example, without effect sizes to guide readers, it is possible that an inappropriate level of 
importance will be attached to variables that are only weakly associated with cannabis 
use, simply because the relationship was reported as being statistically significant.  
  
Clinical Significance 
Similarly, studies that report statistical significance and not clinical significance, also only 
tell one part of the story. Inexplicably, while a few researchers have reported that their 
statistically significant results were not actually clinically relevant [e.g., 36,40], it is rare 
for authors to discuss clinical significance at all. Thus, while the cannabis literature 
contains many reports of statistically significant differences between cannabis users and 
non-users or between light and heavy users, it is possible that these group differences may 
not be clinically significant. For example, a deficit in reaction time or verbal memory 
measured within a laboratory setting may have no impact on an individual’s performance 
at work, ability to fulfill role responsibilities, or social competence, and as such, may not 
represent use-related harms or problems. The lack of consideration and discussion of 




clinical significance in the literature has, therefore, left us with limited understanding of 
the impact of cannabis use on the day-to-day lives of users.  
 
LIMITATIONS ASSOCIATED WITH APPROACHES TO STUDYING 
CANNABIS USE 
Ultimately, what is known and unknown about cannabis users and cannabis use is largely 
due to the approaches employed by researchers to study this phenomenon. Studies 
investigating cannabis use typically follow one of two approaches: either non-users/never 
used vs. current users; or infrequent/light/non-dependent use vs. frequent/ 
heavy/dependent use. The former approaches are typically employed to investigate 
cannabis use in the general population, commonly recruiting university students or being 
based on a subset of items from large general population household or school-based 
surveys [41]. In contrast, the latter approaches generally include more rigorous 
assessments of cannabis use, and typically recruit treatment-seeking/referred users.  
 
There are several drawbacks associated with these approaches to investigating cannabis 
use. For example, studies comparing non-users/never used and current users often assess 
only a limited range of cannabis use factors, such as frequency of use, onset of use, or 
dependence, and ignore the fact that individuals who have never used cannabis are likely 
to differ from users in numerous ways beyond just their use or non-use [42]. These 
differences may be particularly apparent for younger cohorts, where not using cannabis 
may be considered almost an abnormal behaviour [29,43]. Studies comparing different 
levels of current cannabis use are similarly affected by typically overlooking the 
likelihood that individuals engaging in different patterns of cannabis use are likely to also 
differ in other ways. Additionally, because treatment-seeking/referred users are more 




likely to be dependent and experience more adverse use-related problems than non-
treatment seeking users [41,44], studies that recruit from this population of users do not 
necessarily inform us about the larger (and relatively under-researched) hidden population 
of cannabis users who do not experience difficulties of a magnitude that would lead them 
to seek treatment [44]. As such, both of these approaches to investigating cannabis use 
can lead to studies which lack appropriate control groups and are typically limited by 
inadequate data collection and/or through the recruitment of non-representative cannabis 
users.  
 
Both of these approaches are predominantly employed in the identification of cannabis 
use-related risk factors and, therefore, may have contributed to the large number of 
inconsistencies present in the literature [9]. For example, conflicting findings have been 
reported regarding whether increased risk is associated with: male gender [e.g., 45 vs. 
46]; use of tobacco [e.g., 24 vs. 45],  alcohol [e.g., 17 vs. 46], or other illicit drugs [e.g., 
15 vs. 47]; history of conduct [e.g., 24 vs. 46] or internalizing [e.g., 48 vs. 49] disorders; 
exposure to parental conflict [e.g., 46 vs. 48] or a socio-economically disadvantaged 
childhood [e.g., 24 vs. 46]. It is also evident that identifying possible risk factors has not 
been an effective tool in the prevention or reduction of cannabis use in Western societies 
[50].  
 
In aiming to identify individuals at risk of cannabis use, there is an implicit assumption 
that all use will lead to problematic patterns of use and all use is harmful [41]. However, 
as cannabis use has become relatively normalized amongst young people in Western 
cultures, many potential users do not now fit the stereotypical profile of users alluded to 
by a summary overview of identified risk factors (i.e., young, male, dysfunctional and/or 




disadvantaged background, with delinquent/antisocial behaviour) [29,43]. This type of 
risk factor informed stereotypical profile is evident in the depiction of cannabis users in 
public health campaigns, which typically show only adolescent users. It is possible that 
such campaigns decrease the likelihood of identification of ‘non-typical’ users by health 
professionals, because these cannabis users do not fit the expected profile.  As such, we 
need to ensure that the use of risk factors does not blind us to the heterogeneity of 
cannabis users. Specifically, there is a tendency for a ‘one-size-fits-all’ approach in the 
literature, with some researchers seeking a single solution that suits all (or at least most) 
users, rather than acknowledging that it is likely to be more complex with different 
subgroups of users having different experiences and outcomes of use.  
 
Non-Holistic Studies 
A related issue is the tendency for researchers to view cannabis users through the prism of 
their use, rather than to take a more holistic approach, where research participants are 
viewed as individuals who happen to use cannabis. Non-holistic approaches lead to 
research that focuses on cannabis use/dependence as the primary negative outcome of 
risk-factor studies, or on cannabis use/dependence as the primary contributor to adverse 
life experiences in outcome studies. By focusing on cannabis use as the key ‘adverse’ 
factor in an individual’s life, researchers might overlook important environmental or 
individual factors that may contribute to adverse life circumstances. Thus, although the 
findings from these studies make an important contribution, it is important to 
acknowledge that this represents only part of the story. Non-holistic studies only provide 
a limited contribution to our overall understanding of people who use cannabis, their use 
of the substance, and the consequences of such use.   
 




AVENUES FOR FUTURE RESEARCH 
Several issues covered in this paper are unfortunate by-products of the time and financial 
constraints associated with large population-based cohort and cross-sectional studies 
where cannabis use is just one of many variables under investigation. Nevertheless, the 
quality of the cannabis use-related literature can be improved through the routine 
measurement and control of potentially confounding factors and the publication of effect 
sizes. It is also necessary to broaden our sampling populations in cannabis research to 
incorporate both treatment-seeking/referred and non-treatment seeking users, or at least 
acknowledge that the findings of studies related to treatment-seeking/referred users may 
not be generalizable to non-treatment-seeking user populations. It is worth noting that 
‘snowballing’ [e.g., 15.51] and the Internet [e.g., 27,41,52] have been employed 
successfully for the recruitment of samples of non-treatment seeking cannabis users. 
Additionally, greater consideration needs to be given to the clinical significance of 
research findings so that they can be understood in relation to ‘real world’ differences and 
the true impact of cannabis use on an individual’s ability to function in daily-life can be 
ascertained. 
 
Overcoming methodological differences between studies may be more difficult and it is 
worth noting that some benefit is gained in terms of information about the generalisability 
and general robustness of findings when a broad range of valid measures are employed by 
different researchers. However, it would be useful to have some consensus among 
researchers regarding how substance use, psychosocial and even demographic variables 
are assessed to increase comparability of findings and enable meta-analytic studies. 
Specifically, some of the problems associated with frequency measures could be rectified 
if researchers incorporated a broader range of use-criteria into their assessments. For 




example, in terms of consumption, it would be useful to assess the typical number of days 
per week/month/year on which cannabis was used and the typical number of joints/cones 
consumed on each day of use. This more detailed consumption data, if supplemented with 
information about other aspects of use, such as the quantity (including cannabis to 
tobacco ratio of joints/cones) and quality (type of cannabis, relative potency) of cannabis 
consumed, may go some way to being valid as a proxy measure for dose, in lieu of 
measuring THC/CBD (which is difficult to assess in many studies). Further investigation 
is needed in this area, but it is worth noting the research potential of individual 
assessments of intoxication level as a proxy measure of dose [53].   
 
Additionally, while some researchers [e.g., 17,27,51,54] have assessed problems 
associated with cannabis use alongside dependence criteria, more research is required to 
better understand the types of cannabis use-related problems and harms experienced by 
users in their daily lives and the prevalence and severity of these adverse outcomes. 
Further, when dependence is assessed it may be beneficial to examine the specific criteria 
met by individuals, as well as the total number of criteria endorsed [19]. Importantly, it 
should not be assumed that dependence necessarily equates to problematic or harmful use. 
Nor should it be assumed that a diagnosis of dependence informs us about the impact that 
cannabis use has on an individual’s everyday life. In line with this, there is a need for 
studies that examine a broader range of variables relating to overall patterns of cannabis 
use (e.g., context of use, method of administration, motives for use, subjective effects) to 
gain a greater understanding of differing patterns of use and how these use factors may be 
associated with use-related harms and problems experienced by cannabis users.   
 
 





A more recent approach to understanding cannabis users and their cannabis use is through 
the identification of detailed typologies using cluster and/or latent profiling analyses [e.g. 
28,29,55,56].  The advantage of using a typology, rather than a simple categorisation 
approach using risk factors, is the ability to determine group membership on the basis of a 
larger number of factors. This leads to more detailed descriptions of users, which may, for 
example, enable a greater understanding of the differences between individuals with 
similar frequencies of use, and potentially illuminate the basis for the different outcomes 
of use evident in society. Greater exploration of overall patterns of use will also assist our 
understanding of cannabis use within the context of an individual’s life. This research will 
be beneficial for the development of appropriately targeted and evidence-based treatment 
programs and early intervention and harm minimisation strategies.  
 
CONCLUSIONS 
The existing body of cannabis use-related research contains a number of limitations that 
have contributed to our current inability to state definitively: (a) the nature of the 
association between cannabis use and adverse use-related outcomes; (b) the likelihood of 
users experiencing these outcomes; (c) the severity with which they might be 
experienced; and, (d) the ‘real world’ impact of these outcomes on the ability of users to 
function in daily life.  
 
As such, the limitations in the literature must be addressed so that service providers, 
governments, opinion bodies, and individual users can make informed decisions about 
cannabis use. More detailed characterization of users and a greater understanding of the 
role cannabis use plays in the context of people’s lives are also required so that 




appropriately targeted prevention strategies and treatment interventions may be 
developed. In particular, it is important that public health and education campaigns are as 
accurate as possible when detailing the outcomes of cannabis use and the likelihood of 
individuals experiencing use-related problems. Similarly, all interventions need to be 
evidence-based and appropriately targeted towards individuals who are most likely to 
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